Chief Commercial Officer

Regulatory actions for June 6, 2025

EC approves Santen’s Ryjunea to slow progression of pediatric myopia

EC approves Santen’s Ryjunea to slow progression of paediatric myopia

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Senior Director, Compliance

Sydnexis Inc. is a clinical-stage biopharmaceutical company dedicated to improving pediatric eye health through innovative treatments. As the Senior Director of Compliance, you will oversee compliance initiatives, ensuring adherence to ethical business practices and regulatory requirements as the company prepares for its first potential commercial launch.

Sign up with Google

Sign in with Google